RT Journal Article
SR Electronic
T1 Antibody avidity maturation favors SARS-CoV-2 convalescents over vaccinated individuals granting breadth in neutralizability and tolerance against variants
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.09.19.22280078
DO 10.1101/2022.09.19.22280078
A1 Yu Nakagama
A1 Katherine Candray
A1 Natsuko Kaku
A1 Yuko Komase
A1 Maria-Virginia Rodriguez-Funes
A1 Rhina Dominguez
A1 Tomoya Tsuchida
A1 Hiroyuki Kunishima
A1 Etsuko Nagai
A1 Eisuke Adachi
A1 Dieudonné Mumba Ngoyi
A1 Mari Yamasue
A1 Kosaku Komiya
A1 Kazufumi Hiramatsu
A1 Naoto Uemura
A1 Yuki Sugiura
A1 Mayo Yasugi
A1 Yuka Yamagishi
A1 Hiroshige Mikamo
A1 Satoshi Shiraishi
A1 Takehiro Izumo
A1 Sachie Nakagama
A1 Chihiro Watanabe
A1 Yuko Nitahara
A1 Evariste Tshibangu-Kabamba
A1 Hiroshi Kakeya
A1 Yasutoshi Kido
YR 2022
UL http://medrxiv.org/content/early/2022/09/19/2022.09.19.22280078.abstract
AB Background The durability and cross-neutralizability of protective antibodies against evolving SARS-CoV-2 variants are primary concerns in mitigating (re-)exposures. The role of antibody maturation, the process whereby selection of higher avidity antibodies augments host immunity, to determine SARS-CoV-2 neutralizability was investigated.Methods Sera collected from SARS-CoV-2 convalescent individuals at 2- or 10-months after recovery, and BNT162b2 vaccine recipients at 3 or 25 weeks post-vaccination, were analyzed. Anti-spike IgG avidity was measured on a urea-treated ELISA platform. Neutralizing ability of antibodies was assessed by surrogate virus neutralization. Fold change between variant and wild-type antigen neutralizability was calculated to infer breadth of neutralizability.Results Compared with early-convalescence, the avidity index of late-convalescent sera was significantly higher (median 37.7 (interquartile range 28.4–45.1) vs. 64.9 (57.5–71.5), p < 0.0001), indicative of progressive antibody maturation extending months beyond acute-phase illness. The urea-resistant, high-avidity fraction of IgG was best predictive of neutralizability (Spearman’s r = 0.49 vs. 0.67 for wild-type; 0.18–0.52 vs. 0.48–0.83 for variants). Higher-avidity convalescent sera showed greater cross-neutralizability against SARS-CoV-2 variants (p < 0.001 for Alpha; p < 0.01 for Delta and Omicron). Vaccinees experienced delayed maturation kinetics, translating to limited breadth of neutralizability at week-25 post-vaccination which was only comparable to that of early-convalescence.Conclusions Avidity maturation grants broader neutralizability that is resilient against emerging SARS-CoV-2 variants. With immunopotentiation through repeat vaccinations becoming a pivotal strategy to accomplish herd immunity, understanding the variable longitudinal evolutions of the two building blocks of ‘hybrid immunity’ is crucial.Competing Interest StatementY.N. and Y.K. report equity ownership of Quantum Molecular Diagnostics, an Osaka Metropolitan University spinout targeting infectious diseases to develop innovative diagnostics. Y.N. and Y.K. also report receiving financial support outside of this work from Abbott Japan LLC, Japan.Funding StatementThis research was supported by the Japan Agency for Medical Research and Development [grant numbers JP20jk0110021 to Y.N., JP20wm0125003 and JP20he1122001 to Y.K.]; the Japan Society for the Promotion of Science KAKENHI [21K09078 to N.K., 22K15927 to Y.N.]; and the Osaka Metropolitan University Strategic Research Grant [grant number OCU-SRG2021_YR09 to Y.N.]. The authors also received support from the Osaka Metropolitan University Special Reserves Fund for COVID-19 and the Shinya Yamanaka Laboratory COVID-19 Private Fund.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research was approved by the Ethical Committee of Osaka Metropolitan University Graduate School of Medicine (#2020-003).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript.